跳至主要内容
临床试验/IRCT20090813002342N9
IRCT20090813002342N9已完成4 期

The comparison of the efficacy of Iranian Deferasirox (Osveral®) and Exjade® on serum ferritin in patients with major beta-thalassemia

Sari University of Medical Sciences0 个研究点目标入组 90 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
90

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 years 至 no limit(—)
性别
All

入选标准

  • Male or female patients with ß-thalassemia major
  • Age>2 year
  • Ferritin level above 1000 mg/dL or the volume of blood transfusion above 100 mL/kg

排除标准

  • Patients with pregnancy or breast-feeding state
  • Progressive or persistent increase in the creatinine level
  • Any cardiac, auditory or ophthalmic problems
  • Hepatitis B (HBV) or C (HCV) and human immunodeficiency virus (HIV) infections
  • Persistent liver transaminases above 5-fold of the normal level
  • Severe nausea and vomiting
  • Hypersensitivity to deferasirox
  • Sever skin rashes
  • Progressive proteinuria
  • Non-compliant or unreliable patients

研究者

发起方
Sari University of Medical Sciences

相似试验